Rosmarinic Acid Mitigates Mitochondrial Dysfunction and Spinal Glial Activation in Oxaliplatin-induced Peripheral Neuropathy
- 225 Downloads
Chemotherapy-induced peripheral neuropathy (CIPN) is a dose-limiting complication which develops as a consequence of treatment with chemotherapeutic agents like oxaliplatin and is a mainstay of therapy for colorectal cancer. Ever since CIPN was identified, understanding its exact pathomechanisms remains a clinical challenge. The role of mitochondrial dysfunction and glial cell activation has surfaced in the etiology of CIPN. Rosmarinic acid (RA), a known mitoprotectant exerts neuroprotection against the oxidative stress and neuroinflammation in various disease conditions. Hence, in the present study, we investigated the effect using rosmarinic acid (25 and 50 mg/kg, po) in the experimental model of oxaliplatin-induced peripheral neuropathy (OIPN) in rats. Results showed that RA significantly (p < 0.001) prevented the functional deficits, reversed oxaliplatin-induced mechanical allodynia and cold hyperalgesia in rats. It reduced the oxidative stress, improved the mitochondrial function, and prevented the oxaliplatin-induced loss of ATP levels. RA significantly (p < 0.01) inhibited the spinal glial cell activation and suppressed the expression of inflammatory markers. RA treatment also resulted in the activation of adenosine monophosphate-activated protein kinase (AMPK) in the peripheral nerves and dorsal root ganglion (DRG) which also might have contributed to its neuroprotective actions. In vitro screening also revealed that RA did not compromise the anti-cancer activity of oxaliplatin in colon cancer cells (HT-29). Taken together, the above results demonstrate the therapeutic activity of RA against the oxaliplatin-induced mitochondrial dysfunction and neuroinflammation and thus, suggest its potential for the management of OIPN.
KeywordsRosmarinic acid Oxaliplatin Mitochondrial dysfunction Peripheral neuropathy Neuroinflammation Dorsal root ganglion (DRG)
The authors would like to acknowledge the financial support from the Department of Pharmaceuticals, Ministry of Chemical and Fertilizers, and NIPER-Hyderabad for their support to carry out the study.
Compliance with Ethical Standards
Conflicts of Interest
The authors declare that they have no competing interests.
- 13.Chowdhury SKR, Smith DR, Saleh A, Schapansky J, Marquez A, Gomes S, Akude E, Morrow D et al (2012) Impaired adenosine monophosphate-activated protein kinase signalling in dorsal root ganglia neurons is linked to mitochondrial dysfunction and peripheral neuropathy in diabetes. Brain 135(6):1751–1766. https://doi.org/10.1093/brain/aws097 CrossRefGoogle Scholar
- 16.Melemedjian OK, Asiedu MN, Tillu DV, Sanoja R, Yan J, Lark A, Khoutorsky A, Johnson J et al (2011) Targeting adenosine monophosphate-activated protein kinase (AMPK) in preclinical models reveals a potential mechanism for the treatment of neuropathic pain. Mol Pain 7(1):70PubMedPubMedCentralGoogle Scholar
- 19.Bayrasy C, Chabi B, Laguerre M, Lecomte J, Jublanc E, Villeneuve P, Wrutniak-Cabello C, Cabello G (2013) Boosting antioxidants by lipophilization: a strategy to increase cell uptake and target mitochondria. Pharm Res 30(8):1979–1989. https://doi.org/10.1007/s11095-013-1041-4 CrossRefPubMedGoogle Scholar
- 20.Gamaro GD, Suyenaga E, Borsoi M, Lermen J, Pereira P, Ardenghi P (2011) Effect of rosmarinic and caffeic acids on inflammatory and nociception process in rats. Int Sch Res Notices 2011Google Scholar
- 30.Komirishetty P, Areti A, Yerra VG, Ruby PK, Sharma SS, Gogoi R, Sistla R, Kumar A (2016) PARP inhibition attenuates neuroinflammation and oxidative stress in chronic constriction injury induced peripheral neuropathy. Life Sci 150:50–60. https://doi.org/10.1016/j.lfs.2016.02.085 CrossRefPubMedGoogle Scholar
- 35.Komirishetty P, Areti A, Sistla R, Kumar A (2016) Morin mitigates chronic constriction injury (CCI)-induced peripheral neuropathy by inhibiting oxidative stress induced PARP over-activation and neuroinflammation. Neurochem Res 41(8):2029–2042. https://doi.org/10.1007/s11064-016-1914-0 CrossRefPubMedGoogle Scholar
- 37.Kramer KA, Oglesbee D, Hartman SJ, Huey J, Anderson B, Magera MJ, Matern D, Rinaldo P et al (2005) Automated spectrophotometric analysis of mitochondrial respiratory chain complex enzyme activities in cultured skin fibroblasts. Clin Chem 51(11):2110–2116. https://doi.org/10.1373/clinchem.2005.050146 CrossRefPubMedGoogle Scholar
- 40.Mannelli LDC, Zanardelli M, Failli P, Ghelardini C (2013) Oxaliplatin-induced oxidative stress in nervous system-derived cellular models: Could it correlate with in vivo neuropathy? Free Radic Biol Med 61:143–150. https://doi.org/10.1016/j.freeradbiomed.2013.03.019 CrossRefGoogle Scholar
- 49.Yerra VG, Kumar A (2016) Adenosine monophosphate-activated protein kinase abates hyperglycaemia-induced neuronal injury in experimental models of diabetic neuropathy: effects on mitochondrial biogenesis, autophagy and neuroinflammation. Mol Neurobiol 54(3):2301–2312. https://doi.org/10.1007/s12035-016-9824-3 CrossRefPubMedGoogle Scholar
- 51.Ling Y-Z, Li Z-Y, Ou-Yang H-D, Ma C, Wu S-L, Wei J-Y, Ding H-H, Zhang X-L et al (2017) The inhibition of spinal synaptic plasticity mediated by activation of AMP-activated protein kinase signaling alleviates the acute pain induced by oxaliplatin. Exp Neurol 288:85–93. https://doi.org/10.1016/j.expneurol.2016.11.009 CrossRefPubMedGoogle Scholar